BR112013022230A2 - composto de fórmula, utilização do composto de fórmula, processos, composições e utilizações substancialmente inovadores - Google Patents

composto de fórmula, utilização do composto de fórmula, processos, composições e utilizações substancialmente inovadores

Info

Publication number
BR112013022230A2
BR112013022230A2 BR112013022230A BR112013022230A BR112013022230A2 BR 112013022230 A2 BR112013022230 A2 BR 112013022230A2 BR 112013022230 A BR112013022230 A BR 112013022230A BR 112013022230 A BR112013022230 A BR 112013022230A BR 112013022230 A2 BR112013022230 A2 BR 112013022230A2
Authority
BR
Brazil
Prior art keywords
compound
formula
compositions
innovative processes
substantially innovative
Prior art date
Application number
BR112013022230A
Other languages
English (en)
Inventor
Frederick Boylan Jonh
M Mikulski Stanislaw
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013022230A2 publication Critical patent/BR112013022230A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composto de fórmula, utilização do composto de fórmula, processos, composições e utilizações substancialmente inovadores a presente invenção se refere aos novos regimes de dosagem para o inibidor de gama-secretase de 2,2-dimetil-n-((s)-6-oxo-6, 7-diidro-5hdibenzo[b,d]azepin-7-il)-n'(2,2,3,3,3-pentafluoro-propil)-malomida, que maximiza a atividade antitumoral enquanto mantém os níveis aceitáveis de toxicidade.
BR112013022230A 2011-03-02 2012-02-28 composto de fórmula, utilização do composto de fórmula, processos, composições e utilizações substancialmente inovadores BR112013022230A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448216P 2011-03-02 2011-03-02
PCT/EP2012/053338 WO2012116975A1 (en) 2011-03-02 2012-02-28 Method for administration of a gamma secretase inhibitor

Publications (1)

Publication Number Publication Date
BR112013022230A2 true BR112013022230A2 (pt) 2019-01-08

Family

ID=45787194

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013022230A BR112013022230A2 (pt) 2011-03-02 2012-02-28 composto de fórmula, utilização do composto de fórmula, processos, composições e utilizações substancialmente inovadores

Country Status (10)

Country Link
US (2) US20120225860A1 (pt)
EP (1) EP2680854A1 (pt)
JP (1) JP2014506904A (pt)
KR (1) KR20140145939A (pt)
CN (1) CN103533942A (pt)
BR (1) BR112013022230A2 (pt)
CA (1) CA2828296A1 (pt)
MX (1) MX2013009955A (pt)
RU (1) RU2013142014A (pt)
WO (1) WO2012116975A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
WO2019226690A1 (en) * 2018-05-21 2019-11-28 New York University Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711470B1 (en) 2003-09-09 2009-04-15 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activtiy of gamma-secretase
AU2009203776A1 (en) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Use of a gamma-secretase inhibitor for treating cancer

Also Published As

Publication number Publication date
US20140357620A1 (en) 2014-12-04
CN103533942A (zh) 2014-01-22
US20120225860A1 (en) 2012-09-06
MX2013009955A (es) 2013-10-01
JP2014506904A (ja) 2014-03-20
EP2680854A1 (en) 2014-01-08
KR20140145939A (ko) 2014-12-24
RU2013142014A (ru) 2015-04-10
WO2012116975A1 (en) 2012-09-07
CA2828296A1 (en) 2012-09-07

Similar Documents

Publication Publication Date Title
NI201400036A (es) Compuestos con actividad nematicida
ECSP18048718A (es) Imidazolilimidazoles condensados como compuestos antivirales
GEP20166496B (en) Substituted nucleosides, nucleotides and analogs thereof
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
DOP2015000289A (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
CR20140519A (es) Derivados de benzamida para la inhibición de la actividad de abl 1, abl 2 y bcr-abl 1
DOP2014000090A (es) Compuestos con actividad nematicida
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
CR20140084A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
UY33735A (es) Compuestos antivirales
MX339873B (es) Inhibidores de serina/treonina cinasa.
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
IN2014CN04530A (pt)
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
BR112014018135A8 (pt) Produto farmacêutico e uso do produto farmacêutico
NZ711192A (en) Process for making benzoxazepin compounds
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]